Clover Biopharmaceuticals, a global clinical-stage biotech company that develops and commercialises transformative biologic therapies, announced on Tuesday the completion of an oversubscribed Series C funding round at $230 million.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in